These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 15671556)

  • 1. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
    de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
    Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
    de Jonge ME; Huitema AD; Holtkamp MJ; van Dam SM; Beijnen JH; Rodenhuis S
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):370-8. PubMed ID: 15838656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
    De Jonge ME; Mathôt RA; Van Dam SM; Beijnen JH; Rodenhuis S
    Cancer Chemother Pharmacol; 2002 Sep; 50(3):251-5. PubMed ID: 12203108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
    Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S
    Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.
    Huitema AD; Spaander M; Mathĵt RA; Tibben MM; Holtkamp MJ; Beijnen JH; Rodenhuis S
    Ann Oncol; 2002 Mar; 13(3):374-84. PubMed ID: 11996467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy.
    de Jonge ME; Mathôt RA; Dalesio O; Huitema AD; Rodenhuis S; Beijnen JH
    Bone Marrow Transplant; 2002 Nov; 30(9):593-7. PubMed ID: 12407434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen.
    Ekhart C; Rodenhuis S; Beijnen JH; Huitema AD
    Ther Drug Monit; 2009 Feb; 31(1):95-103. PubMed ID: 19155964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency.
    Ekhart C; Kerst JM; Rodenhuis S; Beijnen JH; Huitema AD
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):375-9. PubMed ID: 18431571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
    de Jonge ME; Huitema AD; van Dam SM; Rodenhuis S; Beijnen JH
    Ther Drug Monit; 2005 Dec; 27(6):756-65. PubMed ID: 16306851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin.
    de Jonge ME; Huitema AD; van Dam SM; Beijnen JH; Rodenhuis S
    Cancer Chemother Pharmacol; 2005 May; 55(5):507-10. PubMed ID: 15685452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
    Huitema AD; Mathôt RA; Tibben MM; Schellens JH; Rodenhuis S; Beijnen JH
    Clin Pharmacol Ther; 2000 Jun; 67(6):621-30. PubMed ID: 10872644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens.
    Huitema AD; Kerbusch T; Tibben MM; Rodenhuis S; Beijnen JH
    Cancer Chemother Pharmacol; 2000; 46(2):119-27. PubMed ID: 10972481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer.
    Rodenhuis S; Westermann A; Holtkamp MJ; Nooijen WJ; Baars JW; van der Wall E; Slaper-Cortenbach IC; Schornagel JH
    J Clin Oncol; 1996 May; 14(5):1473-83. PubMed ID: 8622061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
    Chen TL; Kennedy MJ; Anderson LW; Kiraly SB; Black KC; Colvin OM; Grochow LB
    Drug Metab Dispos; 1997 May; 25(5):544-51. PubMed ID: 9152592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
    Anderson LW; Chen TL; Colvin OM; Grochow LB; Collins JM; Kennedy MJ; Strong JM
    Clin Cancer Res; 1996 Sep; 2(9):1481-7. PubMed ID: 9816324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sparse sampling design for therapeutic drug monitoring of sequentially administered cyclophosphamide, thiotepa, and carboplatin (CTC).
    de Jonge ME; Huitema AD; Rodenhuis S; Beijnen JH
    Ther Drug Monit; 2005 Jun; 27(3):393-402. PubMed ID: 15905813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin.
    Ekhart C; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
    Pharmacogenet Genomics; 2008 Nov; 18(11):1009-15. PubMed ID: 18854779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
    Chen TL; Passos-Coelho JL; Noe DA; Kennedy MJ; Black KC; Colvin OM; Grochow LB
    Cancer Res; 1995 Feb; 55(4):810-6. PubMed ID: 7850794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer.
    Petros WP; Broadwater G; Berry D; Jones RB; Vredenburgh JJ; Gilbert CJ; Gibbs JP; Colvin OM; Peters WP
    Clin Cancer Res; 2002 Mar; 8(3):698-705. PubMed ID: 11895898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy.
    de Jonge ME; Huitema AD; Beijnen JH; Rodenhuis S
    Br J Cancer; 2006 May; 94(9):1226-30. PubMed ID: 16622453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.